Safe from over- or underdosing

Long-lasting and precise dosing of medication thanks to an oil-hydrogel mixture

24-Feb-2020 - Using a mixture of oil droplets and hydrogel, medical active agents can be not only precisely dosed, but also continuously administered over periods of up to several days. The active agents inside the active droplets are released at a constant rate, decreasing the risk of over- or ...

One dose of aspirin doesn’t fit all

17-Jul-2018 - About one billion people worldwide take regular aspirin, usually to prevent heart attacks or strokes. Researchers have shown that ‘one-dose-fits-all’ use of aspirin to prevent heart attacks, stroke or cancer, is ineffective or harmful in the majority of people, and that a more tailored strategy ...

BioInvent reports clinical hold on BI-505 phase II study

09-Nov-2016 - BioInvent International has received verbal notice from the U.S. Food and Drug Administration that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInvent has not ...

Freie Universität first institution in Germany to integrate medication management into the pharmacy study program

01-Nov-2016 - The Institute of Pharmacy at Freie Universität Berlin is the first of its kind in Germany to integrate the field of medication management into the education of its pharmacy students. The goal is to put theoretical knowledge into practice even before the students have completed their study ...

Positive result for POWTECH and TechnoPharm 2014

More international: over one-third of the exhibitors and visitors come from abroad

07-Oct-2014 - POWTECH and TechnoPharm 2014 can be summed up positively after three days of productive exhibition activity and knowledge transfer. With altogether 929 exhibitors from 30 countries and some 15,000 trade visitors, it is the world’s largest and most important event for new trends in processing and ...

TNO will deliver technology that makes conducting studies in infants feasible

TNO and European consortium members receive a 1.2 million euro European research grant to improve drug development for infants

13-May-2011 - A scientific programme to investigate new ways to develop drugs for infants received 1.2 million euro European research grant from PRIOMEDCHILD ERA-NET. Research groups across Europe, including innovation organisation TNO, participate in this major programme.Infants (children from 0 - 2 years) ...

Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema

30-Nov-2010 - Pharming Group NV announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor ("rhC1INH") in patients with Hereditary Angioedema (HAE). The study is an open-label exploratory phase II study of the safety and prophylactic effect ...

Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

17-Nov-2010 - Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and the ...

Action Pharma initiates phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

10-Nov-2010 - Action Pharma A/S has administered the first dose to the first patient in a phase IIb clinical trial being undertaken in the USA and Denmark with its leading drug candidate AP214. This follows the positive results obtained on safety, tolerability and efficacy in the phase IIa clinical trial ...

AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316

09-Nov-2010 - AiCuris announced the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing. AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the ...